All publications
Efficient skin delivery: no compromise with Transcutol®
OutsourcingPharma - Nov 2015
This white paper describes Transcutol®, the highest purified pharmaceutical grade of Diethylene Glyceryl monoEthylEther (DEGEE).
Scientific publications asserting the safety of Transcutol® are listed to highlight the non-skin irritant property of Transcutol®. Moreover, solvent properties of Transcutol® are described and solubility data in different solvents are given to illustrate the remarkable solvent capacity of Transcutol®.
This exceptional safety and solvent property make Transcutol® an ideal chemical penetration enhancer for topical formulations, where efficiency and non skin irritancy are key success factors. Examples of commercial uses of DEGEE are cited to illustrate the versatility of use of this excipient in many different topical dosage forms. Practical information is also given for the formulation of Transcutol® in many topical dosage forms.
Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity
International Journal of Pharmaceutics, Volume 495, Issue 1, Pages 385-392 - Nov 2015
This article describes the work undertaken in Gattefossé R&D labs (St Priest) to develop lipid formulations for low to medium lipophilicity API: piroxicam, nifedipine and curcumin and evaluate the effect of in-vitro digestion on the solubilizing capacity of the formulations.
Reaching milestones in lipid-based formulations: from effective prediction to successful development
Sep 2015
This white paper describes the important milestones achieved in lipid based formulation (LBF) development for oral drug delivery. Collaborative research between academic and industrial partners has increased understanding of the functional properties of lipid excipients and the role they play in solubilizing poorly water soluble compounds. It has also led to the development of in vitro – in vivo predictive analytical tools. The key scientific articles describing these milestones are collected in this one White Paper, providing a single source of practical information for those interested in lipid formulation development.
Influence of Formulation Factors and Compression Force on Release Profile of Sustained Release Metoprolol Tablets using Compritol® 888 ATO as Lipid Excipient
Indian J Pharm Sci 2015;77(5): 620-625 - Sep 2015
Release profile of metoprolol from sustained release tablets using Compritol® 888 ATO as SR lipid matrix agent showed high reliability. Different sources of active ingredient and batches of Compritol® were evaluated at different compression forces and in dissolution media containing or not ethanol. The formulation appeared to be very robust and is not affected by these variables. Therefore Compritol® offers great potential in the formulation of reliable SR tablets.
Size characterization of commercial micelles and microemulsions by Taylor dispersion analysis
International Journal of Pharmaceutics, Volume 492, Issues 1–2, Pages 46-54 - Aug 2015
New insights into the stability of SR lipid matrix tablets
CRS Annual Meeting – Edinburgh (Scotland) - Jul 2015
In vitro lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic extract.
Drug Development and Industrial Pharmacy - Volume 41 - Issue 10 https://doi.org/10.3109/03639045.2014.972412 - 2015
Continuous twin screw melt granulation of glyceryl behenate: Development of controlled release tramadol hydrochloride tablets for improved safety.
International Journal of Pharmaceutics, Volume 487, Issues 1–2, Pages 72-80 https://doi.org/10.1016/j.ijpharm.2015.03.058 - Jun 2015
The objective of this study was to develop a continuous granulation process for direct production of granules using this technique with glyceryl behenate as a binder, evaluate the properties of the resulting granules and develop controlled release tablets containing tramadol HCl.
Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations. 5. Lipolysis of Representative Formulations by Gastric Lipase
Pharmaceutical Research volume 32, pages 1279–1287 DOI: 10.1007/s11095-014-1532-y - Apr 2015